January 2017, Volume 3, Issue 1

January 2017

Volume 3, Issue 1

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.

Table of Contents

January 2017 Issue

Marrow-Minded

Sunday, January 1st, 2017
In November’s Editor’s Corner, David Steensma, MD, recounted the “absurdly exotic experience” of eating bone marrow in a café in Milan after speaking about...

Making a Hematology Wishlist, and Checking it Twice

Sunday, January 1st, 2017
Happy New Year! Can you believe it’s 2017 already? Another holiday season passed, another calendar page flipped, another year gone by. I thought that I...

January 2017 Issue

New National Academy of Medicine Members, NIH’s High-Risk High-Reward Program Awards, and more

Sunday, January 1st, 2017
National Academy of Medicine Elects 79 New Members The National Academy of Medicine (NAM) announced the election of 70 regular members and 9 international members...

Pulling Back the Curtain: Ross Levine, MD

Sunday, January 1st, 2017
What was your first job? My first summer jobs were at the publishing company where my mother was employed. I worked there for four summers...

ASH Scholar Award Recipients, Visitor Training Program Open, and more

Sunday, January 1st, 2017
2017 ASH Scholar Award Recipients Announced For more than 30 years, the ASH Scholar Awards have financially supported fellows and junior faculty as they transition...

January 2017 Issue

Predatory Publishing: The Dark Side of the Open-Access Movement

Sunday, January 1st, 2017
In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available...

January 2017 Issue

How long should a patient continue anticoagulation and should she continue during pregnancy?

Sunday, January 1st, 2017
This month, Jean Marie Connors, MD, discusses how long a 31-year-old patient should continue anticoagulation and the recommendations for pregnancy.A 31-year-old female, who had...

How long should a patient continue anticoagulation and should she continue during pregnancy?

Sunday, January 1st, 2017
Here's how readers responded to a Consult-a-Colleague question about anticoagulation during pregnancy. First, although I don’t disagree with rivaroxaban in this case, it has neither...

January 2017 Issue

AMA Announces Support for Value-Based Pricing

Sunday, January 1st, 2017
The American Medical Association (AMA) voiced its support for value-based drug pricing in an initiative that “ at changing the fundamentals of prescription drug...

Mixed Results for Fostamatinib in Studies of Immune Thrombocytopenia

Sunday, January 1st, 2017
Data from two double-blind studies of the SYK inhibitor fostamatinib in adult patients with chronic/persistent immune thrombocytopenia (ITP) showed disparate results. Combined data, however,...

FDA Approves Daratumumab Combination for Multiple Myeloma

Sunday, January 1st, 2017
The FDA approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least...

HHS and NIH Announce New Requirements for Clinical Trials in an Effort to Improve...

Sunday, January 1st, 2017
The U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) announced new requirements for registering and reporting clinical...

FDA Grants Priority Review to Midostaurin for Acute Myeloid Leukemia

Sunday, January 1st, 2017
The U.S. Food and Drug Administration (FDA) granted priority review to midostaurin for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) or advanced...

In Utero Cytomegalovirus Infection Increases Risk of Developing Acute Lymphocytic Leukemia in Pediatric Patients

Sunday, January 1st, 2017
Children who had in utero cytomegalovirus (CMV) infection are more likely to develop childhood acute lymphocytic leukemia (ALL) than matched controls without infection, suggesting...

Lestaurtinib Does Not Improve Survival for Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Sunday, January 1st, 2017
Adding the FLT3 inhibitor lestaurtinib to standard firstline chemotherapy in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) does not improve survival rates,...

LYRIC Study: In the Age of Immunomodulatory Therapy, Do We Need New Lymphoma Response...

Sunday, January 1st, 2017
Since the first internationally accepted response criteria, the Lugano Classification Response Criteria, were published in 1999, advances in immunomodulatory therapies that affect imaging interpretation...

Lenalidomide Shows Some Antitumor Activity in Patients With Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma

Sunday, January 1st, 2017
Patients with adult T-cell leukemia/lymphoma (ATLL) that is resistant to chemotherapeutic regimens have few treatment options. Following a phase I study determining the maximum-tolerated...

Examining the Link Between Cirrhosis and Venous Thromboembolism

Sunday, January 1st, 2017
A meta-analysis published in Thrombosis and Haemostasis, by Pasquale Ambrosino, MD, from the Department of Clinical Medicine and Surgery at the Federico II University...

January 2017 Issue

Anti-CD19 CAR T-Cell Therapy Has High Response Rate in Refractory, Aggressive Non-Hodgkin Lymphoma

Sunday, January 1st, 2017
For patients with chemo-refractory, aggressive non-Hodgkin lymphoma (NHL), treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (known as KTE-C19) induced a CR rate...

PERSIST-2: Pacritinib Compared With Best Available Therapy for Patients With Myelofibrosis and Thrombocytopenia

Sunday, January 1st, 2017
In the phase III PERSIST-2 trial, the multi-tyrosine kinase inhibitor pacritinib met one of two co-primary endpoints, demonstrating a significant reduction in spleen volume...

Ibrutinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease After Transplant

Sunday, January 1st, 2017
The Bruton tyrosine kinase inhibitor ibrutinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several B-cell malignancies and,...

StaMINA: Second AHCT and Post-Transplant Consolidation Therapy Offer No Benefit Over Single Transplant

Sunday, January 1st, 2017
For patients with multiple myeloma (MM), more treatment does not necessarily mean better outcomes, according to results from the phase III StaMINA trial, which...

Prolonging Progression-Free Survival With Obinutuzumab-Based Induction in Patients With Previously Untreated Follicular Lymphoma

Sunday, January 1st, 2017
According to results from the phase III GALLIUM study, patients with previously untreated follicular lymphoma (FL) may benefit from frontline therapy with obinutuzumab, a...

Attempting to Reduce the Chemotherapy Burden of Children With Acute Lymphocytic Leukemia

Sunday, January 1st, 2017
Reduced-intensity treatment was inferior to standard-intensity treatment in duration of disease-free survival (DFS) in pediatric patients with acute lymphocytic leukemia (ALL) who have standard-risk...

Improving Quality of Life Through Gene Therapy for Patients With Hemophilia B

Sunday, January 1st, 2017
Preliminary data from an ongoing phase I/II trial suggest that patients with hemophilia B produced factor IX (FIX) at sufficient levels after receiving a...

Reducing Pain Crises With Novel Selectin Inhibitor in Patients With Sickle Cell Disease

Sunday, January 1st, 2017
Results from the SUSTAIN trial found that the monoclonal antibody crizanlizumab, which targets anti-P-selectin, reduces the frequency of pain crises by nearly half, compared...
SHARE